SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 3/22/2017 3:37:11 PM - Followers: 192 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 03/17/2017 04:17:50 PM
CVM News: Current Report Filing (8-k) 03/10/2017 04:34:30 PM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 03/09/2017 04:16:58 PM
CVM News: CEL-SCI Announces $1.5 Million Registered Direct Offering 03/09/2017 08:00:00 AM
CVM News: Current Report Filing (8-k) 03/07/2017 06:02:43 AM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#10776   Right on top of things Mick...check around 6 Foxwoods Man 03/22/17 03:37:11 PM
#10775   so f.d.a. problem ????? 'Cel-Sci (CVM)' mick 03/22/17 01:00:36 PM
#10774   CVM News: Proxy Statement - Notice of Shareholders mick 03/22/17 12:57:20 PM
#10773   Cel-Sci Corp. ($0.0 (CVM) mick 03/22/17 12:57:12 PM
#10772   good morning, cvm mick 03/22/17 12:56:36 PM
#10771   Read the last 2 prospectus. It's the 2nd learning curve 03/22/17 11:49:56 AM
#10770   Spidy, based on my text below, I'm pretty warfaretrader 03/22/17 09:21:02 AM
#10769   This is way oversold, time to double down. kpisme 03/22/17 09:17:38 AM
#10768   Well put.... Foxwoods Man 03/22/17 08:59:33 AM
#10767   I would agree with FM. They effectively only Spideyboy 03/22/17 03:19:35 AM
#10766   I forgot to mention. The only reason I learning curve 03/22/17 12:49:38 AM
#10765   Really, I'm not totally sold on r/s myself. learning curve 03/22/17 12:45:08 AM
#10764   Your case for the r/s is pretty strong. lightrock 03/22/17 12:24:30 AM
#10763   It could. I don't think there is a learning curve 03/21/17 11:08:36 PM
#10762   Coming from you? That makes sense. You wouldn't learning curve 03/21/17 10:57:05 PM
#10761   I think the arb case gets extended at learning curve 03/21/17 10:42:56 PM
#10760   Never seen a r/s visited and not implemented learning curve 03/21/17 10:07:38 PM
#10759   I believe the arbitration and FDA lift both trickledownfacists 03/21/17 05:39:06 PM
#10758   And IMHO I humbly disagree with you Fox. warfaretrader 03/21/17 04:19:16 PM
#10757   IMHO the ONLY event that will make this Foxwoods Man 03/21/17 12:36:49 PM
#10756   Grabbed some .09s GMONEY4 03/21/17 12:25:50 PM
#10755   They have no other options to raise capital. Foxwoods Man 03/21/17 12:16:37 PM
#10754   LC, the main reason, well the only reason warfaretrader 03/21/17 09:18:09 AM
#10753   Questions How many times do you prep a shareholder lightrock 03/21/17 02:09:50 AM
#10752   Here is a blunt way to put it. learning curve 03/21/17 01:09:05 AM
#10751   Rallies start when investors are willing to pay learning curve 03/21/17 12:52:32 AM
#10750   I agree with some things warfare has said learning curve 03/20/17 10:14:48 PM
#10749   I think if one comes they both come warfaretrader 03/20/17 05:11:15 PM
#10748   Do you think FDA LIFT or Arbitration results trickledownfacists 03/20/17 04:43:30 PM
#10747   Read the 10k ; how much cash they learning curve 03/20/17 04:37:26 PM
#10746   IMO, look at it like a bridge loan. learning curve 03/20/17 04:34:03 PM
#10745   Somebody who wants to see it through and learning curve 03/20/17 04:31:56 PM
#10744   Their average cash burn is a little less trickledownfacists 03/20/17 04:28:25 PM
#10743   No they don't. They need funding, warrant exercise learning curve 03/20/17 04:26:37 PM
#10742   Agreed, seems they are kicking the van down trickledownfacists 03/20/17 02:41:33 PM
#10741   It feels as if they are delaying everything sinity 03/20/17 01:50:19 PM
#10740   It doesn't have to do with the burning sinity 03/20/17 01:46:26 PM
#10739   Who would buy in millions of shares knowing sinity 03/20/17 01:43:16 PM
#10738   The went through around $3.8 million between the Foxwoods Man 03/20/17 01:43:16 PM
#10737   Yes they do, they raised $5 mil over trickledownfacists 03/20/17 01:34:14 PM
#10736   Cvm doesn't even have enough money to get learning curve 03/20/17 01:33:01 PM
#10735   I thought PPS would drop a tad today Foxwoods Man 03/20/17 01:13:49 PM
#10734   Info sinity 03/20/17 01:07:04 PM
#10733   FM, pps, this what you expected after the sinity 03/20/17 01:06:46 PM
#10732   Market cap should not change with a R/S. Foxwoods Man 03/20/17 10:44:18 AM
#10730   Why, because history will repeat itself as it steve2150 03/20/17 09:31:25 AM
#10729   I hope....Cvm gets all clear from FDA (including Foxwoods Man 03/19/17 09:18:29 AM
#10728   We can only hope this isn't the scenario warfaretrader 03/19/17 09:15:17 AM
#10727   Using the literal definition of a R/S the Foxwoods Man 03/19/17 09:05:38 AM
#10726   So beside all this, owner of shares at KingLui 03/19/17 02:19:12 AM
PostSubject